A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Phase 1

Terminated

• Conditions: Age-Related Macular Degeneration

• Registration Number: NCT00090532
• Lead Sponsor: Pfizer

Brief Summary

AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Study First Submitted: 2004-08-26
• Study First Submitted QC: 2004-08-30
• Study First Posted: 2004-08-31
• Study Completion: 2006-08
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-26
• Last Update Posted: 2011-05-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 155

Inclusion Criteria

• Male and/or female subjects >=55 years of age
• Subfoveal choroidal neovascularization complicating age-related macular degeneration
• Subjects who are informed of, and willing and able to comply with, the investigational nature of the study and are able to provide written informed consent in accordance with institutional and regulatory guidelines

Exclusion Criteria

• Other serious ocular diseases or conditions, including diabetic retinopathy and glaucoma, that are likely to compromise visual acuity within 1 year

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To evaluate the ocular and systemic safety of the study drug

Secondary Outcome Measures

Name	Time	Method
To evaluate the visual acuity change after study treatment

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇬🇧 London, United Kingdom